Right ventricular failure is the leading cause of death in patients with severe pulmonary arterial hypertension. While It is known that right heart failure represents a major co-morbidity in advanced lung disease, little is known about right ventricular adaptation and failure within the context of secondary pulmonary hypertension. Interaction between the heart and pulmonary circulation plays an important role in pulmonary vascular stiffening and increased tone thus conferring additional hemodynamic stress on the RV. The initial response of both the pulmonary vasculature and the heart to hemodynamic and neurohormonal stress is hypertrophy. Numerous studies on the /e/i^ ventricle have concluded that hypertrophy often progresses to cardiac dysfunction and maladaptive remodeling culminating in heart failure. Similar events are proposed for the right heart. Currently, we lack an understanding of the fundamental relationship between hypertrophy and failure in the RV as well as the interaction between the heart and lung vasculature, particularly in the setting of secondary PAH. We postulate that common stress pathways in the heart and pulmonary circulation promote increased vascular resistance/remodeling and RV hypertrophy/failure. Consistent with this thesis, preliminary data suggest that increased reactive oxygen species (ROS) signaling and NO synthase uncoupling in both the RV and pulmonary vasculature represent a central pathological stress response in chronic hypoxia and cigarette smoke exposure. Secondary reduction in NO bioavailability in the RV, caused by eNOS dimer formation and increases in pathological eNOS derived ROS/superoxide anion (Oz')-generation is associated with the development of contractile dysfunction and maladaptive remodeling. Preliminary data implicate upstream NADPH oxidase activation in NOS uncoupling. Thus it is hypothesized that a convergent stress response involving ROS generation and eNOS uncoupling drives reduced NOcGMP signaling to produce maladaptive right ventricular and pulmonary vascular remodeling during hemodynamic and/or neurohormonal stress. The following aims will test this hypothesis: (1) determine the role of eNOS uncoupling as a common mechanism in the development of pulmonary vascular and right ventricular maladaptive remodeling;(2) investigate the 'kindling'role of NADPH oxidase (Nox)-derived ROS in eNOS dysfunction promoting feed-fonward ROS generation that leads to vascular and RV maladaptive remodeling;(3) develop and test small molecule inhibitors targeting pathological ROS signaling to prevent RV failure in murine and primate models of PAH.
The proposed studies will add greatly to our basic understanding of cardiopulmonary disease. It is expected that the present proposal will result in new therapeutics to directly target the mechanistic pathways involved in the remodeling of the pulmonary vasculature and right ventricle in conditions of pulmonary hypertension.
| Freeman, Bruce A; O'Donnell, Valerie B; Schopfer, Francisco J (2018) The discovery of nitro-fatty acids as products of metabolic and inflammatory reactions and mediators of adaptive cell signaling. Nitric Oxide 77:106-111 |
| Villacorta, Luis; Minarrieta, Lucia; Salvatore, Sonia R et al. (2018) In situ generation, metabolism and immunomodulatory signaling actions of nitro-conjugated linoleic acid in a murine model of inflammation. Redox Biol 15:522-531 |
| Remy, Kenneth E; Cortés-Puch, Irene; Solomon, Steven B et al. (2018) Haptoglobin improves shock, lung injury, and survival in canine pneumonia. JCI Insight 3: |
| Rom, Oren; Khoo, Nicholas K H; Chen, Y Eugene et al. (2018) Inflammatory signaling and metabolic regulation by nitro-fatty acids. Nitric Oxide : |
| D'Amore, Antonio; Fazzari, Marco; Jiang, Hong-Bin et al. (2018) Nitro-Oleic Acid (NO2-OA) Release Enhances Regional Angiogenesis in a Rat Abdominal Wall Defect Model. Tissue Eng Part A 24:889-904 |
| Schopfer, Francisco J; Vitturi, Dario A; Jorkasky, Diane K et al. (2018) Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases. Nitric Oxide 79:31-37 |
| Farkas, Daniela; Thompson, A A Roger; Bhagwani, Aneel R et al. (2018) Toll-like Receptor 3 is a Therapeutic Target for Pulmonary Hypertension. Am J Respir Crit Care Med : |
| Goncharov, Dmitry A; Goncharova, Elena A; Tofovic, Stevan P et al. (2018) Metformin Therapy for Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction versus Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 198:681-684 |
| Rafikova, Olga; Williams, Elissa R; McBride, Matthew L et al. (2018) Hemolysis-induced Lung Vascular Leakage Contributes to the Development of Pulmonary Hypertension. Am J Respir Cell Mol Biol 59:334-345 |
| Hensley, Matthew K; Levine, Andrea; Gladwin, Mark T et al. (2018) Emerging therapeutics in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 314:L769-L781 |
Showing the most recent 10 out of 182 publications
